FDA Says Eli Lilly Overstates Benefits Of Adcirca
The U.S. Food and Drug Administration has warned Eli Lilly & Co. that marketing materials for its hypertension drug Adcirca overstate its effectiveness and omit information about risks associated with the...To view the full article, register now.
Already a subscriber? Click here to view full article